Clinical Study Results
The table below shows the serious adverse reactions that happened during the
study. Some participants had more than one serious adverse reaction.
Serious adverse reactions during the study
Group 1 Group 2
Savolitinib Sunitinib
(Out of 33 (Out of 27
Serious adverse reaction participants) participants)
Lung infection 3.0% (1) 0.0% (0)
Allergic reaction to a drug 3.0% (1) 0.0% (0)
Blood clot in a vein 3.0% (1) 0.0% (0)
Build-up of fluid in the stomach area 3.0% (1) 0.0% (0)
Swelling in the legs and arms 3.0% (1) 0.0% (0)
A high amount of a liver enzyme (ALT) 3.0% (1) 0.0% (0)
A high amount of a liver enzyme (AST) 3.0% (1) 0.0% (0)
Low level of blood cells that help
0.0% (0) 3.7% (1)
clotting (platelets)
Fast and abnormal heartbeat 0.0% (0) 3.7% (1)
Large increase in blood pressure
0.0% (0) 3.7% (1)
without organ damage
PRCC got worse 0.0% (0) 3.7% (1)
How many participants had adverse reactions?
• 78.3% of participants had adverse reactions during the study. This was 47 out
of 60 participants.
• 66.7% of participants had adverse reactions after taking savolitinib during the
study. This was 22 out of 33 participants.
• 92.6% of participants had adverse reactions after taking sunitinib during the
study. This was 25 out of 27 participants.
There were 15.2% of participants who stopped taking savolitinib because of
adverse events they had during the study. This was 5 out of 33 participants.
There were 14.8% of participants who stopped taking sunitinib because of adverse
events they had during the study. This was 4 out of 27 participants.
9